Stage 1: History
A 21-year-old female college student from New Delhi presents to the emergency department with a 10-day history of progressive fatigue, weakness, light-headedness, exertional dyspnea, and dark tea-colored urine, culminating in a brief syncopal episode without injury. She reports no vomiting, diarrhea, or decreased oral intake.
Past Medical & Menstrual History: History of irregular menstrual periods without menorrhagia. Her only medication is an oral contraceptive pill. She reports no use of tobacco, alcohol, herbal supplements, or illicit substances. She is not sexually active, has no recent travel history, and has no family history of metabolic, autoimmune, or hematologic disorders.
Review of Systems: No fever prior to admission, no chest pain, cough, skin rash, joint pains, or abdominal pain.
Hello, Chief Resident here.
Key Findings: A 21-year-old female presenting with acute symptomatic anemia (fatigue, dyspnea, syncope) and dark tea-colored urine, strongly indicating severe hemolysis (intravascular or extravascular) without active bleeding.
Differential Diagnoses:
1. Autoimmune Hemolytic Anemia (AIHA) (40%): Classic presentation in a young female for warm/cold AIHA leading to rapid red cell destruction and hemoglobinuria.
2. G6PD Deficiency (25%): Acute hemolytic crisis triggered by an unrecorded oxidative stress, infection, or food item.
3. Infectious Hemolysis (e.g., Malaria / Blackwater Fever) (15%): High relevance given residency in New Delhi; P. falciparum can cause profound intravascular hemolysis.
4. Paroxysmal Nocturnal Hemoglobinuria (PNH) (10%): Acquired stem cell disorder presenting with episodic dark urine and anemia in young adults.
5. Thrombotic Microangiopathy (TTP/HUS) (10%): Urgent exclusion required for microangiopathic hemolytic anemia despite the absence of neurological or renal symptoms.
Recommended Initial Tests:
1. CBC with Reticulocyte Count & Peripheral Smear (evaluating spherocytes, schistocytes, bite cells).
2. Hemolysis Markers: LDH, Haptoglobin, Indirect Bilirubin, Urine Dipstick & Hemosiderin.
3. Direct Antiglobulin Test (DAT / Direct Coombs Test).
4. Malaria Smear & Rapid Diagnostic Test (RDT).
5. G6PD Enzyme Assay.
Hello Attending Consultant here
Critique: Solid initial framework emphasizing hemolysis workup, but underweights OCP-associated risks (e.g., atypical HUS/TMA) and omits urgent exclusion of hemoglobinopathies or Wilson disease in this demographic. G6PD less probable in females without X-inactivation skew. Prioritize smear review before enzyme assays.
Top 3 DDx:
1. Warm AIHA (OCP-triggered or idiopathic)
2. PNH (classic hemoglobinuria + young adult)
3. Malaria (endemic exposure, blackwater fever)
Specific points:
1. Add CBC indices + smear for schistocytes/spherocytes immediately.
2. Include coagulation panel + ADAMTS13 to rule out TTP.
3. Obtain free plasma Hb and urine hemosiderin for intravascular confirmation.
4. Flow cytometry for GPI-anchored proteins (PNH screen).
5. Wilson workup: ceruloplasmin, slit-lamp if liver enzymes rise.
6. Hold OCP; consider Emicizumab or eculizumab contingency if PNH/TMA confirmed.
7. Serial neuro checks + renal function q6h.
Hello, Expert Clinician here.
Best current unifying diagnosis: Acute symptomatic intravascular hemolytic anemia with hemoglobinuria; paroxysmal nocturnal hemoglobinuria (PNH) is the leading etiologic consideration given unexplained tea-colored urine and anemia in a young adult, but confirmation is essential.
Top differentials
- Warm autoimmune hemolytic anemia: Commoner than PNH in young women; favored by spherocytes and positive DAT, although hemoglobinuria is less characteristic.
- G6PD-related hemolysis: Fits acute intravascular hemolysis, but no oxidative trigger is reported and clinically significant disease is less common in females; testing during crisis may be falsely normal.
- TTP/other thrombotic microangiopathy: Critical not to miss, but currently lacks documented thrombocytopenia, renal injury, neurologic abnormalities, or schistocytes.
- Malaria: Geographic exposure is relevant, but absent fever or recent travel lowers probability.
- Hemoglobinuria from nonhemolytic causes: Rhabdomyolysis is less likely without myalgias; urinalysis microscopy distinguishes hemoglobin from intact RBCs.
Key pivot: Confirm whether dark urine represents hemoglobinuria and determine immune versus nonimmune hemolysis.
Immediate move: Obtain CBC/platelets, reticulocytes, smear, bilirubin, LDH, haptoglobin, creatinine, urinalysis with microscopy, and DAT; type/crossmatch and transfuse if unstable or severely anemic. If DAT-negative intravascular hemolysis is confirmed, order high-sensitivity FLAER/CD55/CD59 flow cytometry for PNH.
Teaching pearl: Tea-colored urine with positive heme but few/no RBCs suggests hemoglobinuria or myoglobinuria—not hematuria.
Stage 2: Exam + Initial Workup
Physical Examination:
Vitals: Febrile with temperature 38.1°C (100.6°F), Pulse 105 beats/min (sinus tachycardia), Respiratory Rate 18 breaths/min, BP 127/59 mmHg, SpO2 99% on room air.
General: Scleral icterus is present. No lymphadenopathy or skin lesions.
Cardiovascular / Pulmonary: Regular tachycardia, no heart murmurs, friction rubs, or gallops. Lungs clear bilaterally.
Abdomen / Neurologic: Abdomen soft, non-tender without organomegaly or ascites. Alert and oriented with intact motor strength, sensation, gait, and coordination.
Laboratory Investigations:
- Complete Blood Count: Marked leukocytosis with WBC 47,300/µL (67% polymorphonuclear cells, 7% band forms [leukemoid reaction]). Hemoglobin 3.9 g/dL with MCV 136 fL (marked macrocytosis). Platelet count 249,000/µL. Reticulocyte count 36% (marked reticulocytosis).
- Liver Function & Metabolic Panel: Serum Creatinine 2.1 mg/dL (190 µmol/L), Serum Albumin 2.6 g/dL. AST 50 U/L, ALT 9 U/L. Alkaline Phosphatase 8 U/L (markedly low/suppressed). Total Bilirubin 6.8 mg/dL, Direct Bilirubin 2.7 mg/dL (Indirect Bilirubin 4.1 mg/dL). Coagulation: INR 1.6, aPTT 38.0 seconds (normal 22–32s).
- Urinalysis: 3+ blood, 2+ protein, 4–10 RBCs/hpf.
Initial Management & Transfusion Response:
Transfusion of 3 units PRBC increased Hemoglobin to 7.8 g/dL. Post-transfusion blood smear revealed immature granulocytes, nucleated RBCs, marked anisopoikilocytosis, and numerous spherocytes and echinospherocytes.
Hello, Chief Resident here.
Updated Key Findings: Severe acute intravascular hemolysis (Hb 3.9 g/dL, reticulocytes 36%, hemoglobinuria), AKI (Cr 2.1 mg/dL), leukemoid reaction (WBC 47.3k), spherocytes, and a strikingly suppressed Alkaline Phosphatase (8 U/L) with an ALP-to-Total Bilirubin ratio < 2.
Differential Diagnoses:
1. Fulminant Wilson Disease (60%): Profoundly low ALP, an ALP:Bilirubin ratio < 1.2, Coombs-negative acute intravascular hemolytic crisis, and AKI in a young adult strongly signal acute copper toxicity.
2. Autoimmune Hemolytic Anemia (AIHA) (25%): Supported by marked spherocytosis, massive reticulocytosis, and leukemoid response; requires DAT confirmation.
3. Paroxysmal Nocturnal Hemoglobinuria (PNH) (10%): Explains severe hemoglobinuria, acute renal impairment, and macrocytosis.
4. G6PD Deficiency / Oxidative Stress (5%): Fits echinospherocytes and acute intravascular release, though less typical in females.
Recommended Next Steps:
1. Serum Ceruloplasmin & 24-hour Urinary/Serum Copper (urgent Wilson workup).
2. Slit-lamp examination (Kayser-Fleischer rings).
3. **Direct Antiglobulin Test
Hello Attending Consultant here
Critique: Excellent pivot to Wilson’s—low ALP, ALP:bili ≪4, Coombs-neg intravascular hemolysis + AKI + coagulopathy is near-pathognomonic. However, plan still under-prioritizes immediate DAT (AIHA remains live) and infection work-up given fever/leukemoid reaction; smear echinospherocytes also raise oxidative injury.
Top 3 DDx:
1. Fulminant Wilson disease (copper-induced hemolysis)
2. Warm AIHA (DAT pending; spherocytes dominant)
3. PNH or malaria superinfection (endemic + hemoglobinuria)
Specific points:
1. STAT DAT + eluate before further transfusion.
2. Serum/urine copper + ceruloplasmin + KF rings now.
3. Blood cultures, thick/thin smear, procalcitonin.
4. Correct coagulopathy (FFP/vit K) pre-procedure.
5. Urgent hepatology/transplant consult; prepare for chelation or plasma exchange.
6. Serial ammonia, ABG, neuro checks for ALF.
7. Hold OCP; monitor for further hemolysis post-transfusion.
Hello, Expert Clinician here.
Best unifying diagnosis: Wilson disease presenting as an acute copper-mediated, likely DAT-negative intravascular hemolytic crisis with AKI and evolving acute liver failure. Profound anemia, hemoglobinuria, indirect hyperbilirubinemia, reticulocytosis, low albumin, and INR 1.6 support this.
Key pivot: The extraordinarily low alkaline phosphatase (8 U/L) relative to bilirubin—ALP:total bilirubin ≈1.2 (<4)—plus AST:ALT >2.2 is highly suggestive of acute liver failure from Wilson disease. Macrocytosis is largely explained by extreme reticulocytosis.
Top differentials
- Warm AIHA: Numerous spherocytes fit; obtain DAT urgently. It does not explain the strikingly suppressed ALP well.
- PNH: Hemoglobinuria and AKI fit, but preserved platelets and liver-test pattern argue against it.
- Oxidative hemolysis/G6PD deficiency: Possible, but no trigger or bite cells reported.
- TMA/TTP: Unlikely with normal platelets, no schistocytes, and intact neurologic status.
- Malaria/sepsis: Fever and leukemoid reaction warrant cultures and malaria testing, but do not unify the biochemical pattern.
Most important move: Urgent hepatology/transplant-center referral. Send DAT, serum/urine copper, ceruloplasmin, slit-lamp examination, and hemolysis studies; consider plasma exchange as a copper-removal bridge while assessing for liver transplantation.
Teaching pearl: Ceruloplasmin may be normal in fulminant Wilson disease; biochemical ratios can be more diagnostically useful.
Stage 3: Refractory Hemolysis, Immunosuppression & Temporary Stabilization
Laboratory Biomarkers & Autoimmune Evaluation:
- Hemolysis Panel: Serum LDH 735 U/L (normal 120–240), Serum Haptoglobin <8 mg/dL (severely depleted, normal 22–239).
- Direct Antiglobulin Test (DAT / Coombs test): NEGATIVE on two separate occasions.
- Iron & Nutritional Markers: Serum Iron 111 µg/dL, TIBC 190 µg/dL, Transferrin Saturation 58%. Vitamin B12 1,790 pg/mL, Folic acid 12.7 ng/mL.
- Imaging: ECG, CXR, and abdominal ultrasound normal except for mild gallbladder wall thickening. Urine beta-hCG: Negative.
Clinical Course & Immunosuppressive Trial:
- On Day 2, Hemoglobin rapidly dropped back to 4.8 g/dL. Bone marrow aspirate and biopsy showed 70% cellularity with trilineage hyperplastic maturation without blasts or dysplasia. Urine/blood cultures: Sterile.
- Initiated IV Methylprednisolone (1 mg/kg/day) for presumed Coombs-negative autoimmune hemolytic anemia (AIHA).
- Refractory Hemolysis: Continued requiring frequent PRBC transfusions. G6PD level, PNH flow cytometry, HIV, Mycoplasma, Parvovirus B19, and hemoglobin electrophoresis: All Normal/Negative. Serum Creatinine peaked at 2.7 mg/dL on HD 4 and normalized. Platelets nadired at 141,000/µL on HD 5; ADAMTS13 activity normal.
- Rituximab Therapy: Given IV Rituximab (375 mg/m²) on HD 7 for refractory Coombs-negative hemolytic anemia. Hemoglobin stabilized at 8.4 g/dL; transitioned to oral prednisone on HD 9 and discharged on HD 10. Completed 4 weekly rituximab doses with apparent clinical stabilization.
- 4-Week Post-Discharge Labs: Hb 12.1 g/dL, Platelets 203,000/µL, LDH 244 U/L, Haptoglobin <8 mg/dL, AST 59 U/L, ALT 79 U/L, Total Bilirubin 2.2 mg/dL.
Hello, Chief Resident here.
Updated Key Findings: DAT-negative intravascular hemolysis showing apparent remission (Hb 12.1 g/dL, LDH 244 U/L) following high-dose steroids and Rituximab. However, persistent undetectable haptoglobin (<8 mg/dL) and mild transaminitis indicate ongoing subclinical hemolysis. Workup for PNH, G6PD, TTP, and common infections is negative.
Differential Diagnoses:
1. Coombs-Negative Warm AIHA (60%): Favored by dramatic clinical response to B-cell depletion/steroids; negative standard DAT is explained by low-affinity IgA/IgM or low-density IgG.
2. Wilson Disease (25%): Remains a vital consideration given Stage 2's severely suppressed ALP (8 U/L); transient copper-release crises can temporarily abate, but persistent transaminitis warrants formal exclusion.
3. Atypical HUS / Complement-Mediated TMA (10%): Transient AKI and platelet nadir fit, though recovery without eculizumab makes this less likely.
4. Rare Erythrocyte Enzymopathy/Membranopathy (5%): Non-immune destruction masked by initial high reticulocyte turn-over.
Prioritised Next Steps:
1. Serum Ceruloplasmin & 24-hour Urinary Copper (rule out Wilson disease).
2. Slit-lamp Examination (Kayser-Fleischer rings).
3. Enhanced/Super-sensitive DAT (Flow Cytometry/IgA-IgM specific).
4. Complement Panel (C3, C4, Factor H/I) (evaluate atypical TMA).
5. Structured Steroid Taper with Weekly Hemolysis Monitoring.
Hello Attending Consultant here
Critique: Over-relies on steroid/rituximab response to lock in Coombs-neg AIHA; ignores that Wilson hemolysis can spontaneously wax/wane and that rising ALT + persistently undetectable haptoglobin signal incomplete resolution. Low-ALP clue from Stage 2 remains unaddressed—fatal if missed. Complement panel low-yield post-recovery.
Top 3 DDx:
1. Fulminant Wilson disease (copper hemolysis + ALF prodrome)
2. True Coombs-negative warm AIHA (low-affinity Ig)
3. Occult enzymopathy/membranopathy unmasked by stress
Specific points:
1. STAT ceruloplasmin, serum/urine copper, KF rings—non-negotiable.
2. Recheck ALP + ALP:bili ratio now.
3. Hepatology consult ± liver biopsy/quantitative copper.
4. Enhanced DAT (anti-IgA/IgM/flow) only after Wilson excluded.
5. Slow steroid taper; weekly LDH/haptoglobin/Hb.
6. Avoid further empiric IS until copper studies clear.
7. Genetic ATP7B if biochemicals equivocal.
Hello, Expert Clinician here.
Best unifying diagnosis: Wilson disease causing an acute copper-mediated intravascular hemolytic crisis with hepatic dysfunction and transient pigment nephropathy. The strongest clues remain age 21, profoundly suppressed ALP (8 U/L), ALP:bilirubin ratio ≈1.2, coagulopathy, indirect hyperbilirubinemia, DAT-negative hemolysis, AKI, and subsequent transaminitis.
Top differentials
- DAT-negative warm AIHA: Spherocytes and apparent steroid/rituximab response support it, but two negative DATs and markedly low ALP are unexplained. Improvement may reflect transfusion, natural fluctuation, or immunosuppression coinciding with stabilization.
- Hereditary membrane/enzyme disorder: Spherocytes could fit, but abrupt onset, no family history, and negative initial studies argue against it.
- PNH/TMA/G6PD deficiency: Effectively weakened by negative flow cytometry, normal ADAMTS13 with near-normal platelets, and normal G6PD testing.
Key pivot: Clinical response to immunosuppression does not establish immune causation; persistent absent haptoglobin and evolving liver abnormalities keep Wilson disease central.
Most important next move: Urgent hepatology evaluation with repeat ALP/INR, ceruloplasmin, serum copper, 24-hour urinary copper, slit-lamp examination, and ATP7B testing; consider quantitative hepatic copper if results conflict. Refer promptly to a transplant center if coagulopathy or hemolysis worsens.
Teaching pearl: Fulminant Wilson disease may have normal ceruloplasmin and no Kayser–Fleischer rings.
Stage 4: Relapse, Hepatic Deterioration & Targeted Diagnostic Testing
Relapse at 3 Months:
Three months post-admission, the patient presented with recurrent dark-colored urine, fatigue, progressive scleral icterus, and frank jaundice.
- Readmission Labs: WBC 20,100/µL, Hemoglobin 10.1 g/dL, Platelets 189,000/µL, Reticulocytes 5.3%. Serum Creatinine 0.4 mg/dL, Albumin 2.6 g/dL.
- Severe Hepatic & Coagulation Dysfunction: AST 123 U/L, ALT 40 U/L (AST > ALT ratio), Alkaline Phosphatase 57 U/L (persistently suppressed relative to severe hyperbilirubinemia), Total Bilirubin 28.3 mg/dL (Direct Bilirubin 18.7 mg/dL). INR 2.2, aPTT 39.6 seconds.
Abdominal Imaging & Serology:
- Ultrasound & CT Abdomen: Demonstrated innumerable small echogenic liver nodules, micronodular liver surface contour (cirrhosis), borderline splenomegaly (12.7 cm), and moderate ascites.
- Serum Ferritin: 4,304 ng/mL. Viral hepatitis (HBV, HCV, EBV) & Autoimmune liver panel (ANA, ASMA, AMA, LKM-1): All Negative.
Targeted Copper Diagnostics:
- Serum Ceruloplasmin: <4 mg/dL (markedly low; normal 18–42 mg/dL).
- 24-Hour Urinary Copper: 4,703 µg/24 hr (severely elevated; normal <55 µg/24 hr).
- Slit-Lamp Ophthalmologic Exam: Confirmed bilateral Kayser-Fleischer (KF) rings at the corneoscleral junction.
Hello, Chief Resident here.
Updated Key Findings: Recurrent Coombs-negative hemolysis, acute-on-chronic liver failure (cirrhosis, ascites, INR 2.2, severe hyperbilirubinemia with suppressed ALP), and pathognomonic Wilson disease markers: ceruloplasmin <4 mg/dL, 24-hour urine copper 4,703 µg, and bilateral Kayser-Fleischer rings.
Differential Diagnoses:
1. Wilson Disease (Fulminant Acute-on-Chronic Liver Failure with Copper-Induced Hemolysis) (95%): Confirmed by Leipzig scoring criteria (KF rings, low ceruloplasmin, urine copper >10x ULN, Coombs-neg hemolysis with low ALP/bilirubin ratio).
2. Autoimmune Hepatitis / AIHA Overlap (3%): Initial steroid/rituximab response misled early management, but negative autoimmune serologies make this untenable as primary.
3. Primary Hemochromatosis / Iron Overload (2%): Elevated ferritin (4,304 ng/mL) reflects acute phase reactant/massive hepatic necrosis rather than primary etiology.
Prioritised Next Steps & Management:
1. Urgent Liver Transplant Referral: Transfer to a liver transplant center immediately; fulminant presentation with high MELD/Leipzig score carries near 100% mortality without transplantation.
2. Extracorporeal Copper Clearance: Initiate Therapeutic Plasma Exchange (TPE) or Molecular Adsorbent Recirculating System (MARS) as a bridge to transplantation.
3. Chelation Therapy: Start Trientine or Penicillamine plus oral Zinc under specialist direction.
4. Genetic Testing: Order ATP7B gene sequencing for the patient and screen first-degree relatives.
Hello Attending Consultant here
Critique: Plan correctly prioritizes transplant and copper removal now that Leipzig criteria confirm Wilson disease; however, it under-emphasizes immediate MELD-Na calculation, infection prophylaxis in decompensated cirrhosis, and family screening urgency. Chelation alone is insufficient bridge in ALF—pair with continuous extracorporeal removal.
Top 3 DDx:
1. Fulminant Wilson disease (confirmed: KF rings, ceruloplasmin <4, urine Cu 4703 µg, low ALP, Coombs-neg hemolysis)
2. AIH overlap (remote; seronegative, prior IS response coincidental)
3. Secondary iron overload/cirrhosis (ferritin reactive, not primary)
Specific points:
1. Calculate MELD-Na/NWI score; activate status-1A listing if eligible.
2. Initiate TPE or albumin dialysis (MARS/Prometheus) STAT for copper clearance.
3. Start trientine + zinc; avoid penicillamine in ALF (worsens neuro).
4. Broad-spectrum abx + SBP prophylaxis; paracentesis if tense ascites.
5. ATP7B sequencing + first-degree relative screening/ceruloplasmin.
6. Serial neuro checks, ammonia, EEG for HE; avoid sedation.
7. Hepatology/transplant ICU transfer now.
Hello, Expert Clinician here.
Best unifying diagnosis: Wilson disease with decompensated acute-on-chronic liver failure and recurrent copper-induced, DAT-negative intravascular hemolysis. Diagnosis is effectively confirmed by Kayser–Fleischer rings, ceruloplasmin <4 mg/dL, urinary copper 4,703 µg/day, cirrhosis, and disproportionally low ALP relative to bilirubin.
Top differentials
- DAT-negative AIHA: Spherocytes and transient improvement with immunosuppression were misleading; it cannot explain the copper studies, cirrhosis, or low ALP.
- Autoimmune/viral hepatitis: Serologies are negative, and the characteristic biochemical and copper profile strongly oppose these.
- Hemochromatosis/HLH: Ferritin 4,304 likely reflects severe hepatic inflammation/necrosis; neither explains KF rings and massive copper excretion.
Key pivot: Relapsing hemolysis accompanied by progressive synthetic failure—not the temporary rituximab response—prompted targeted copper testing.
Most important move: Immediate transfer to a liver-transplant ICU for urgent listing assessment using MELD-Na and the New Wilson Index. Begin therapeutic plasma exchange, or albumin dialysis where available, as a bridge to transplantation; chelation should be specialist-directed and must not delay transplant. Perform diagnostic paracentesis, monitor encephalopathy/glucose/INR, and treat infection if identified.
Teaching pearl: Coombs-negative hemolysis plus jaundice and an ALP:bilirubin ratio <4 is a major warning for fulminant Wilson disease.
Stage 5: Final Results & Clinical Outcome
Final Diagnosis:
Wilson's Disease (Fulminant Hepatic Failure with Coombs-Negative Intravascular Hemolytic Anemia and Leukemoid Reaction) secondary to compound heterozygous ATP7B gene mutations.
Pathophysiologic Mechanism:
Acute hepatocellular necrosis from copper overload releases massive free copper into the circulation. Excess ionic copper inhibits red cell glycolytic enzymes (G6PD, hexokinase) and causes direct oxidative cross-linking of erythrocyte membrane proteins, triggering acute intravascular Coombs-negative hemolysis and a leukemoid reaction. Copper-mediated oxidative damage also inactivates serum alkaline phosphatase, explaining the classic low ALP-to-bilirubin ratio.
Management & Transplantation Outcome:
- Medical Bridge & Liver Transplantation: Medical therapy with Trientine and Zinc Acetate was initiated alongside plasmapheresis and hemodialysis bridge. However, due to progressive fulminant hepatic failure, she underwent emergency Orthotopic Liver Transplantation (OLT) on Hospital Day 6 of readmission.
- Explanted Liver Pathology: Confirmed cirrhosis with heavy periseptal hepatocyte copper accumulation on rhodanine staining; dry weight liver copper content was 526 µg/g (normal 10–35 µg/g).
- Genetic Confirmation & Family Cascade Screening: Genetic testing revealed ATP7B mutations (c.331C->T stop mutation and IVS4-34G->A). Cascade screening of her 18-year-old asymptomatic sister identified low ceruloplasmin/copper and identical ATP7B mutations; early zinc acetate therapy prevented liver failure.
- Long-Term Follow-up: At 1-year post-transplant, the patient has completely normal liver and kidney function, normal cell counts, and is thriving.
Hello, Chief Resident here.
Updated Key Findings: Definitive confirmation of Wilson disease presenting with fulminant liver failure, Coombs-negative intravascular hemolysis, and leukemoid reaction secondary to compound heterozygous ATP7B mutations (c.331C->T and IVS4-34G->A), confirmed by explant hepatic copper (526 µg/g). Excellent 1-year post-OLT recovery and successful early intervention in her asymptomatic sister.
Final Diagnosis:
1. Wilson Disease (ATP7B Compound Heterozygosity) (100%): Unequivocally established via genetic sequencing, rhodanine stain, markedly elevated hepatic dry weight copper, and classic biochemical indices (suppressed ALP, ALP:bilirubin <2).
Key Clinical Pearls:
This case highlights that free copper release causes direct erythrocyte oxidative damage and ALP inactivation, mimicking Coombs-negative AIHA. Immunosuppressive response can be misleading; low ALP relative to severe hyperbilirubinemia should always prompt immediate Wilson testing.
Recommended Post-Transplant Management:
1. Immunosuppression & Allograft Surveillance: Maintain tailored immunosuppression with routine liver enzymes and therapeutic drug monitoring.
2. Complete Cascade Screening: Screen remaining first-degree relatives with ATP7B sequencing and serum ceruloplasmin.
3. Genetic Counseling: Educate patient and family on autosomal recessive inheritance patterns.
4. Ophthalmologic Follow-Up: Serial slit-lamp examinations to track Kayser-Fleischer ring resolution post-transplantation.
Hello Attending Consultant here
Critique: Accurate closure on confirmed Wilson disease via genetics, explant copper quantification, and cascade success. Plan appropriately shifts to post-OLT care but under-emphasizes lifelong copper monitoring nuances, neurologic surveillance (even post-transplant), and donor/recipient matching implications for ATP7B. Overstates “100%” without noting rare phenocopies.
Top 3 DDx:
1. Fulminant Wilson disease (ATP7B compound het; confirmed)
2. Copper toxicosis mimic (e.g., Indian childhood cirrhosis—excluded)
3. Post-transplant AIHA recurrence (remote surveillance needed)
Specific points:
1. Lifelong calcineurin-inhibitor + steroid-sparing IS; protocol biopsies prn.
2. Serial serum/urine copper + ceruloplasmin q3–6 mo initially.
3. Full sibling/parent ATP7B + ceruloplasmin cascade completion.
4. Neurocognitive baseline + KF ring serial exams.
5. Vaccinate pre/post-OLT; PCP/SBP prophylaxis per protocol.
6. Avoid copper-rich diet/supplements indefinitely.
7. Genetic counseling for reproductive risk.
Hello, Expert Clinician here.
Final unifying diagnosis: Genetically confirmed Wilson disease due to compound-heterozygous ATP7B mutations, causing acute-on-chronic fulminant hepatic failure, massive copper release, oxidative DAT-negative intravascular hemolysis, pigment-associated AKI, and a reactive leukemoid response. Explant copper of 526 µg/g and rhodanine-positive deposits provide definitive confirmation.
Retrospective differentials
- DAT-negative warm AIHA: Spherocytes and temporary stabilization after steroids/rituximab mimicked AIHA, but repeated negative DAT, severe hepatic dysfunction, and copper studies refute it.
- PNH/G6PD deficiency/TMA: Hemoglobinuria fit, but flow cytometry, G6PD testing, ADAMTS13, platelet pattern, and smear findings were inconsistent.
- Viral or autoimmune hepatitis: Negative serologies and the characteristic copper phenotype exclude these.
Key pivot: Profoundly low ALP relative to bilirubin, recurrent Coombs-negative hemolysis, AST predominance, and coagulopathy should trigger immediate Wilson testing—not reliance on apparent immunosuppressive response.
Most important management: Emergency liver transplantation, with plasma exchange and renal support as bridges, was lifesaving. Continue transplant surveillance and complete ATP7B-based family screening and genetic counseling; the sister’s presymptomatic treatment demonstrates its value.
Teaching pearl: In a young patient, ALP:bilirubin <4 plus DAT-negative hemolysis is a red flag for fulminant Wilson disease.